June 2022, Vol 12, No 6

Sotorasib (Lumakras) continues to demonstrate durable efficacy in non–­small-cell lung cancer (NSCLC) with KRAS p.G12C mutation at 2-year follow-up of the phase 2 CodeBreaK 100 clinical trial. Read More ›

Have we lost the concept of common sense in our aggressive pursuit of “value” in healthcare? Read More ›

Telehealth is playing a larger role in the delivery of cancer care, but there is more work that needs to be done to permanently increase access, according to a panel of experts during a plenary session at the National Comprehensive Cancer Network (NCCN) 2022 Annual Conference. Read More ›

The number of cancer survivors continues to increase in the United States, which can be attributed to a growing and aging population, as well as recent advances in diagnosis and treatment. Read More ›

The use of a polygenic score (PGS) based on noncancer genetic variations in prostate-specific antigen (PSA) values helped to refine PSA screening in a large group of men without prostate cancer at baseline. Read More ›

Minority and marginalized communities have historically been underrepresented in local and federal governments and in dozens of private sectors globally. Read More ›

Combining the PARP inhibitor olaparib (Lynparza) with abir­aterone acetate (Zytiga) led to a statistically significant and clinically meaningful improvement in radiographic progression-free survival (PFS) versus abiraterone alone in patients with metastatic castration-resistant prostate cancer (mCRPC), regardless of homologous recombination repair (HRR) status, according to results of the phase 3 PROpel trial, presented at the 2022 ASCO Genitourinary Cancers Symposium. Read More ›

Adjuvant pembrolizumab (Keytruda) continued to provide a disease-free survival (DFS) benefit in patients with renal-cell carcinoma (RCC) at intermediate-high or high risk of recurrence after nephrectomy, according to 30-month follow-up data from the KEYNOTE-564 trial presented at the 2022 ASCO Genitourinary Cancers Symposium. Read More ›

Genetic testing is becoming increasingly used in oncology because of its potential to inform surgical decisions and chemotherapy. Read More ›

The Public Health Emergency (PHE), which has been in place since January 27, 2020, is going to end, although the official expiration date has not yet been determined. Many of the regulations built into 2022 final rulings from the Centers for Medicare & Medicaid Services (CMS) tied changes to the expiration of the PHE. Read More ›

Page 1 of 2

Subscribe Today!

To sign up for our free e-Newsletter or print publications, please enter your contact information below.

I'd like to receive:

OPM e-Newsletter
OPM print publication